Pheno Therapeutics is a new biotechnology company founded by the University of Edinburgh and Advent Life Sciences that builds on the ground breaking research of Profs Siddharthan Chandran and Neil Carragher, world class experts in multiple sclerosis and stem cell biology, and phenotypic screening, respectively.
WELCOME TO PHENO THERAPEUTICS
Developing remyelinating therapies for the unmet need for a neuroprotective therapy for Multiple Sclerosis.
Learn More
Developing ground
breaking research
Based in Edinburgh and positioned to deploy the University’s world-leading expertise in phenotypic screening, stem cell technology and myelin biology, we aim to discover and develop small molecule therapeutics that promote remyelination for the treatment of multiple sclerosis.
Pheno Therapeutics aims to identify remyelinating agents: novel drugs that enhance the repair of damaged myelin sheaths in MS patients.
